F5 to Participate in Upcoming Financial Conferences
Get Alerts FFIV Hot Sheet
Join SI Premium – FREE
SEATTLE--(BUSINESS WIRE)-- F5, Inc. (NASDAQ: FFIV) today announced that it will participate in two upcoming financial conferences:
Raymond James 2024 TMT & Consumer Conference – Tuesday, December 10, 2024
F5’s presentation will be webcast live beginning at 1:40 p.m. ET. Interested attendees can access the live webcast via the Events & Presentations tab within the Investor Relations section of f5.com or via this link.
Barclays 22nd Annual Global Technology Conference – Wednesday, December 11, 2024
F5’s presentation will be webcast live beginning at 6:05 p.m. ET. Interested attendees can access the live webcast via the Events & Presentations tab within the Investor Relations section of f5.com or via this link.
Archived versions of both webcasts will be available via F5’s Events & Presentations tab.
About F5
F5 is a multicloud application security and delivery company committed to bringing a better digital world to life. F5 partners with the world’s largest, most advanced organizations to secure every app—on premises, in the cloud, or at the edge. F5 enables businesses to continuously stay ahead of threats while delivering exceptional, secure digital experiences for their customers. For more information, go to f5.com. (NASDAQ: FFIV)
You can also follow @F5 on X or visit us on LinkedIn and Facebook for more information about F5, its partners, and technologies. F5 is a trademark, service mark, or tradename of F5, Inc., in the U.S. and other countries. All other product and company names herein may be trademarks of their respective owners.
SOURCE: F5, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203044803/en/
Suzanne DuLong
(206) 272-7049
[email protected]
Source: F5, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mitsubishi Electric Wholly Acquires Infostellar to Expand Ground Station Services for Satellite Operators
- Final State Budget Brings $5M for New Behavioral Health Pilot to Central Coast
- Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Raymond James, BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share